Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2007

01-01-2007 | Epidemiology

Plasma homocysteine as a metabolic risk factor for breast cancer: findings from a case–control study in Taiwan

Authors: Yu-Ching Chou, Meei-Shyuan Lee, Mei-Hsuan Wu, Hsiu-Lan Shih, Tsan Yang, Cheng-Ping Yu, Jyh-Cherng Yu, Chien-An Sun

Published in: Breast Cancer Research and Treatment | Issue 2/2007

Login to get access
Metadata
Title
Plasma homocysteine as a metabolic risk factor for breast cancer: findings from a case–control study in Taiwan
Authors
Yu-Ching Chou
Meei-Shyuan Lee
Mei-Hsuan Wu
Hsiu-Lan Shih
Tsan Yang
Cheng-Ping Yu
Jyh-Cherng Yu
Chien-An Sun
Publication date
01-01-2007
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9278-9

Other articles of this Issue 2/2007

Breast Cancer Research and Treatment 2/2007 Go to the issue

Preclinical study

The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells

Epidemiology

NSAID use and survival after breast cancer diagnosis in post-menopausal women

Epidemiology

Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM)

Preclinical Study

Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells

Letter to the Editor

COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic for molecular markers

Preclinical Study

Lewis x Antigen Mediates Adhesion of Human Breast Carcinoma Cells to Activated Endothelium. Possible Involvement of the Endothelial Scavenger Receptor C-type Lectin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits